Vivaldi Capital Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Vivaldi Capital Management’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,000	Closed	-$99K	–	262
2021 Q3	$99K	Hold	10,000	–	–	0.02%	319
2021 Q2	$100K	Buy	+10,000	New	+$100K	0.02%	326

Other funds holding EBACU

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

PMAM

Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.39% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.34% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Vivaldi Capital Management's EBACU Position: Q4 2021 in Review

Vivaldi Capital Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q4 2021, closing a stake of 10,000 shares — an estimated $99K sold.

Vivaldi Capital Management first reported a position in EBACU in Q2 2021 and held it in 2 quarters. The position peaked at $100K in Q2 2021. 26 funds tracked by Wall St. Rank hold EBACU as of Q4 2021.

Vivaldi Capital Management reported no remaining European Biotech Acquisition Corp. Units position as of Q4 2021 after selling out during the quarter.
Vivaldi Capital Management sold 10,000 European Biotech Acquisition Corp. Units shares in Q4 2021, an estimated $99K.
Vivaldi Capital Management first reported a position in European Biotech Acquisition Corp. Units in Q2 2021 and held it in 2 quarters.
Vivaldi Capital Management's European Biotech Acquisition Corp. Units position peaked at $100K in Q2 2021.
26 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q4 2021.

Based on Vivaldi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.